Biostone Biologics

Biostone Biologics is a UK-based medtech company established in 2017 specializing in next-generation synthetic bone graft products that mimic natural bone remodeling. Its lead product line "si-Mochi" has received FDA clearance for multiple surgical applications including open and minimally invasive orthopedic procedures as well as veterinary use. The company holds ISO13485 and MDSAP certifications and aims to expand its portfolio into dental indications and new territories globally. Products are based on proprietary biomimetic technologies designed to enhance osteointegration by promoting osteocyte formation. Clinical results summary indicates successful regulatory clearance but no published clinical trial data was identified—commercialization status implies positive safety/performance profile sufficient for market entry under current device regulations. The pipeline includes four main programs at various stages from commercial launch to preclinical development targeting human orthopedics/spine/dental/veterinary markets with global ambitions. Manufacturing capabilities include certified production of medical devices under ISO13485/MDSAP standards; specific details about GMP or biologic/small molecule manufacturing not applicable due to the nature of the products being synthetic biomaterials/devices rather than drugs or biologic therapeutics.